Daniel Blessing

CTO at HAYA Therapeutics

Speaker

Inspired by and dedicated to the premise of programable regulatory genome targeted therapeutics and genetic medicines broadly, Dr. Daniel Blessing is Co-Founder and CTO of HAYA Therapeutics. His role at HAYA is focused on leading R&D to devise and execute strategies to bring assets and drug candidates from early discovery to the translational IND-Enabling stage. As HAYA’s co-founder he was recognized with the Andreas & Thomas Struengmann Award 2024 for their pioneering entrepreneurial vision. Dr. Blessing's scientific background includes post-doctoral research at the University Hospital Lausanne (CHUV) in genetic medicines and RNA-targeting therapeutics for the modulation of regulatory genome derive non-coding RNAs and PhD research at the University of Lausanne/EPFL focused on therapeutic gene delivery and gene therapy approaches using different modalities.